Assetmark Inc. Acquires 580 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Assetmark Inc. increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 18.0% in the third quarter, HoldingsChannel reports. The firm owned 3,808 shares of the company’s stock after buying an additional 580 shares during the period. Assetmark Inc.’s holdings in Denali Therapeutics were worth $111,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EP Wealth Advisors LLC bought a new stake in shares of Denali Therapeutics during the first quarter worth approximately $831,000. Edgestream Partners L.P. bought a new stake in shares of Denali Therapeutics during the first quarter worth approximately $2,301,000. Bayesian Capital Management LP bought a new stake in shares of Denali Therapeutics during the first quarter worth approximately $447,000. Swiss National Bank boosted its holdings in shares of Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock worth $4,477,000 after acquiring an additional 1,500 shares during the period. Finally, Capital Research Global Investors boosted its holdings in shares of Denali Therapeutics by 107.9% during the first quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock worth $124,145,000 after acquiring an additional 3,140,429 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Shares of DNLI opened at $25.05 on Monday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The company has a market cap of $3.61 billion, a P/E ratio of -9.08 and a beta of 1.40. The firm has a 50 day simple moving average of $28.20 and a two-hundred day simple moving average of $24.09.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the business posted ($0.72) EPS. On average, analysts expect that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. The trade was a 50.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the sale, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 86,578 shares of company stock worth $2,474,440. Corporate insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on DNLI shares. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. JPMorgan Chase & Co. dropped their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Jefferies Financial Group lifted their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Citigroup lifted their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Denali Therapeutics in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.